Press "Enter" to skip to content

FDA issues warning letter to Alkermes over opioid addiction treatment ad

Users of Vivitrol as a treatment for opioid dependence should be made aware of the vulnerability to potentially fatal overdose at the end of a dosing interval, after missing a dose, or after discontinuing the treatment, the agency said in the letter dated Dec. 2.

Original source:

Also Read:   Bayer says it is looking into established drugs strategy